The weekly term sheet (31)
Global pharmaceutical and biotech deals surge with $15+ billion in transactions
The pharmaceutical and biotechnology sectors witnessed significant deal activity
Biotech Equity and Stock Option Valuation – A Deep Dive for Founders
Valuing a biotech venture is a bit like valuing a promising but precarious alchemical experiment – full of potential magic, but
Company of the week: Avalyn Pharma - Inhaled Therapeutics for Pulmonary Fibrosis
Avalyn Pharma represents a compelling yet high-risk opportunity in the rapidly evolving pulmonary fibrosis therapeutics market. The company's
Fund of the week: Concentra
Tang Capital's contrarian strategy targets the 300 "zombie" companies holding $30 billion in trapped capital
In
Digital Therapeutics Reimbursement Models in Europe and Asia
Overview of Digital Therapeutics and Reimbursement
Digital therapeutics (DTx) are evidence-based software interventions prescribed to treat or manage medical conditions.
Europe’s Grand HTA Experiment: Unifying Drug Assessments Across the EU
In January 2025, a long-awaited experiment in European healthcare quietly began. For the first time, all EU countries have started
Comparative Regulatory Approaches to AI in Drug Development (as of July 2025)
Advances in artificial intelligence (AI) are rapidly transforming drug development and clinical trials. Medicines regulatory agencies worldwide have responded by
The weekly term sheet (30)
During the week of July 21–25, 2025, the biopharmaceutical industry saw a flurry of deal-making worldwide. This included major
Basics of Pharma Deal Structuring: An Explainer for Biotech Professionals
Most biotech professionals are familiar with science and R&D, but deal press releases often include financial jargon that
Company of the week: Repare Therapeutics - A Contrarian Precision Oncology Company
Disclaimer: This analysis represents an opinion based on publicly available information and should not be considered investment advice. Please conduct
